← Back
Data updated: Jun 28, 2026
FOLDRX PHARMS
Pharma Pharmaceuticals
FOLDRX PHARMS is a pharmaceutical company with 2 FDA-approved products.
2019
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
FDA Novel Drug Designations
(2019) 1 Novel 1 First-in-Class 1 Orphan 1 Breakthrough 1 Priority Review 1 Fast Track
See 1 novel approval →
2019 VYNDAQEL (TAFAMIDIS MEGLUMINE) First-in-Class · Orphan · Breakthrough · Priority Review · Fast Track
FOLDRX PHARMS's Key Drugs
FOLDRX PHARMS's core commercial portfolio centers on VYNDAMAX — its most strategically important drugs approved in the last 15 years.
FOLDRX PHARMS's Recent FDA Approvals
New NDA/BLA approvals for FOLDRX PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
FOLDRX PHARMS's Therapeutic Areas
Disease areas where FOLDRX PHARMS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
FOLDRX PHARMS Pipeline Snapshot
Active clinical trials for FOLDRX PHARMS across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • VYNDAMAX leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling